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Stem cell-based therapies hold considerable promise for many currently devastating neurological disorders.
Substantial progress has been made in the derivation of disease-relevant human donor cell populations.
Behavioral data in relevant animal models of disease have demonstrated therapeutic efficacy for several
cell-based approaches. Consequently, cGMP grade cell products are currently being developed for first in
human clinical trials in select disorders. Despite the therapeutic promise, the presumedmechanism of action
of donor cell populations often remains insufficiently validated. It depends greatly on the properties of the
transplanted cell type and the underlying host pathology. Several new technologies have become available
to probe mechanisms of action in real time and to manipulate in vivo cell function and integration to enhance
therapeutic efficacy. Results from such studies generate crucial insight into the nature of brain repair that can
be achieved today and push the boundaries of what may be possible in the future.Introduction
Most degenerative, vascular, inflammatory, or traumatic neuro-
logical diseases lead to an irreversible demise of brain tissue at
some point during the disease course, which commonly goes
along with deteriorating physical or intellectual function. Apart
from the limited potential for endogenous regeneration in the
human brain, which can be enhanced by rehabilitative training,
treatment of suchdisorders is largely symptomatic. Symptomatic
treatment usually involves the modulation of neurotransmitter
systems and, for a growing number of pathologies, deep brain
stimulation. However, symptomatic therapies often achieve
only transient and partial efficacy and remain ineffective for
several disorders. The identification of disease modifying drugs
is highly desirable and is being pursuedby the pharmaceutical in-
dustry (AlDakheel et al., 2014; Caraci et al., 2013). However, for
most neurological disorders such drugs have not yet reached
the clinic with a few notable exceptions such as in the case of re-
lapsing-remittingmultiple sclerosis (Smith et al., 2010). Given this
medical dilemma, which represents a major socio-economic
burden for many aging societies, experimental stem cell thera-
pies hold considerable promise for brain repair. Research activ-
ities in neural transplantation have steadily increased since the
initial reports of fetal tissue grafting in experimental models of
Parkinson’s disease (PD) (Brundin et al., 1986; Dunnett et al.,
1981) followed by early clinical trials in PD (Lindvall et al., 1989,
1990) and Huntington’s disease (HD) patients (Bachoud-Le´vi
et al., 2000; Reuter et al., 2008). Here we review the progress
and remaining challenges toward the generation of unlimited
numbers of defined human donor cell populations with therapeu-
tic relevance to CNS disorders. We continue to describe the
benefits and caveats that go along with the use of these cell
populations in preclinical studies and impending clinical trials.
We highlight the use of emerging technologies, which are geared
toward increasing therapeutic efficacy, mapping connectivity, orinterrogating mechanisms and therapeutic rationale. The poten-
tial for endogenous regeneration has been reviewed elsewhere
recently (Dimyan and Cohen, 2011; Saha et al., 2012) and is not
discussed here except for selective examples that highlight
specific mechanisms or experimental approaches. We acknowl-
edge that many therapeutic principles have been first described
using rodent primary or mouse embryonic stem cell (ESC)-
derived donor cells. However, since this review focuses on the
prospect for human therapy, studies employing non-human cells
are only mentioned if they demonstrate a unique principle not yet
recapitulated with human cells.
I. Generation of Neural Cell Types from Various Sources
Primary Cells
While a number of non-neural tissue sources such as adrenal
medulla autografts in PD have been used in the past (Backlund
et al., 1985; Madrazo et al., 1987), the main era of neurotrans-
plantation started with the use of fetal brain tissue as human
donor tissue source. Early preclinical studies employed rodent
(Dunnett et al., 1981), and later human (Brundin et al., 1986), cells
derived from the fetal ventral midbrain in experimental models of
PD. These studies provided strong evidence for the survival and
therapeutic efficacy of mesencephalic dopaminergic grafts. As a
consequence, the first clinical transplantation trials utilizing
these cells in PD patients ensued swiftly. Despite promising
data indicating motor recovery in the initial open label studies
(Lindvall et al., 1989, 1990; Wenning et al., 1997), the two dou-
ble-blind, placebo-controlled trials in PD patients (Freed et al.,
2001; Olanow et al., 2003) failed to reach their primary endpoints.
These studies also revealed graft-induced dyskinesias as a trou-
bling side effect, which may be caused by contaminating seroto-
nergic neurons in the donor cell population (Politis et al., 2010)
though other factors may contribute as well. In some cases,
however, grafts have been shown to survive for more than 15Neuron 86, April 8, 2015 ª2015 Elsevier Inc. 187
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as shown by [18F]Fluorodopa positron emission tomography
(PET) scans and postmortem analysis. Also, subgroup analysis
revealed significant effects in patients receiving a transplant un-
der the age of 60 and patients followed for longer periods of time
(Ma et al., 2010). Therefore, multiple factors such as patient se-
lection (age, disease severity, L-Dopa responsiveness) and trial
design (target site, immunosuppression, endpoints) as well as is-
sues related to the donor cell populations are likely critical fac-
tors for success (Barker et al., 2013a). The donor cell populations
in those studies variedwith respect to gestational age, number of
donors, pre-transplantation derivation, and storage as well as
dopamine neuron content. However, beyond confounding bio-
logical and technical factors, obtaining up to seven donors
simultaneously for transplantation of a single PD patient repre-
sents a serious logistical challenge and raises ethical concerns
for a disease affecting millions of patients. In a related approach,
HD patients have been grafted with fetal striatal tissue in small
open label studies as well as in ongoing multicenter efforts
involving several hundred patients. Long-term follow-up in at
least a subset of those studies suggests benefits on motor and
cognitive function for a period of several years following trans-
plantation (Bachoud-Le´vi et al., 2000, 2006; Reuter et al.,
2008). Functional benefits may correlate with the extent of graft
survival as determined by PET imaging (Bachoud-Le´vi et al.,
2006; Barker et al., 2013b; Reuter et al., 2008), though many
other factors likely contribute.
Primary Neural Stem Cells
Given the concerns related to the use of primary fetal cells, a ma-
jor focus in the field has been the generation of scalable cell pop-
ulations that can be developed into standardized and quality
controlled products for future therapeutic use. The ability to
isolate neural stem cells (NSCs) in vitro and evidence of lifelong
neurogenesis in some regions of the mammalian brain, reviewed
in Gage and Temple (2013), argue for NSCs as one potential cell
source. In vitro expanded rat fetalmidbrain precursors have been
shown to recover motor deficits in Parkinsonian animals (Studer
et al., 1998), but the extent of cell expansion is limited using this
approach and has never been developed into robust technology
for use with human cells (Cave et al., 2014; Sa´nchez-Pernaute
et al., 2001). Human NSCs obtained from the fetal telencephalon
were shown to be expandable in vitro after immortalization
(Flax et al., 1998), as neurospheres (Caldwell et al., 2001; Uchida
et al., 2000) or in adherent monolayer cultures (Sun et al., 2008)
in the presence of epidermal and/or fibroblast growth factors
(EGF, FGF). Similarly, multipotent neural progenitor cells were
expanded from several regions of the adult human brain (Nunes
et al., 2003; Walton et al., 2006). These populations were shown
to survive transplantation into immuno-compromised rodents
anddifferentiatemostly into neurons andastrocytes in vivo.How-
ever, fate specification and therapeutic potential of the resulting
neurons appear to be restricted, and differentiation into defined,
authentic neuronal subtypes such as striatal projection neurons
or midbrain dopamine neurons has never been shown. In fact,
continuous exposure to mitogens such as EGF and FGF in the
absence of additional patterning factors seems to interfere with
the fate potential of the region of origin (Jain et al., 2003). In addi-
tion, the progressive switch from neurogenesis to gliogenesis188 Neuron 86, April 8, 2015 ª2015 Elsevier Inc.occurring in many of the primary expanded populations (Naka-
Kaneda et al., 2014; Patterson et al., 2014) can further complicate
the use of NSCs in regenerative therapies. Nevertheless, despite
their limited differentiation potential, NSCs are currently being
tested in a variety of preclinical and clinical applications (see
Primary NSCs).
Neural Cells Derived from Pluripotent Stem Cells
The isolation of human embryonic stem cells (hESCs) (Thomson
et al., 1998) and subsequently induced pluripotent stem cells
(iPSCs) (Takahashi et al., 2007) offered a new strategy to poten-
tially generate any cell type in unlimited numbers. The generation
of differentiated neural cell types from hESCs (Reubinoff et al.,
2001; Zhang et al., 2001) was followed by the derivation of
several developmentally distinct NSC populations (Elkabetz
et al., 2008; Koch et al., 2009) reviewed in Conti and Cattaneo
(2010). These pluripotent stem cell (PSC)-derived NSC popula-
tions displayed properties comparable to primary NSC sources
with respect to expandability and differentiation potential with
improved but still limited ability to control neuron subtype spe-
cific fates. In parallel, several strategies were developed to
generate region specific neurons from human PSCs (hPSCs)
without relying on a NSC intermediate. The strategy of directed
differentiation has gradually evolved toward defined culture sys-
tems. Initial protocols commonly made use of stromal feeder
cells or embryoid body (EB) cultures to enhance neural induction
and further neuronal differentiation (Roy et al., 2006; Vazin et al.,
2008). The increasing understanding of processes that regulate
early mammalian CNS development and the availability of re-
combinant morphogens and growth factors led to a transition
toward more defined differentiation protocols (Pera et al.,
2004). An additional level of sophistication and efficacy was
achieved with the use of small molecules, which activate or
inhibit key developmental pathways such as Wnt, Shh, Activin/
Nodal, BMP, TGF signaling (Smith et al., 2008). Harnessing these
developments, a rapid, highly efficient, and surprisingly facile
protocol has been devised, which generates PAX6+ primitive
neuroectoderm within 10 days by inhibition of transforming
growth factor b (TGF-b) and BMP signaling, also known as
dual SMAD inhibition (dSMADi) (Chambers et al., 2009). The
most attractive feature of dSMADi, however, is its malleability
and modularity. Using the timed addition of one or several other
patterning factors, a multitude of disease-relevant human neural
cell populations have been derived in a systematic manner and
with unprecedented efficiency and purity.
Projection Neurons
Excitatory glutamatergic projection neurons represent the main
building blocks of the human telencephalon (Lui et al., 2011)
and are affected in a large number of neurological diseases
with different etiology. Interestingly, most neural differentiation
protocols, whether feeder or EB based (Elkabetz et al., 2008;
Koch et al., 2009; Li et al., 2005) or based on any form of
SMAD inhibition (Chambers et al., 2009; Espuny-Camacho
et al., 2013), pass through a dorsal telencephalic PAX6/OTX2
double positive intermediate. The acquisition of telencephalic
fates is believed to represent a ground state of neuroepithelial
cells during hPSC differentiation in the absence of additional
patterning factors. Small molecule inhibition of canonical Wnt
signaling was shown to further enhance telencephalic (FOXG1)
Neuron
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of such ground state telencephalic cultures mimics the sequen-
tial generation of cortical layers based on the expression of layer-
specific markers. However, extended in vitro differentiation
periods of 100 days or longer are required to efficiently generate
upper layer neurons under those conditions (Eiraku et al., 2008;
Espuny-Camacho et al., 2013; Shi et al., 2012; van de Leemput
et al., 2014). Morphologically, the resulting neurons have a pyra-
midal shape and express markers of glutamatergic cortical neu-
rons. Ongoing studies are focused on further directing cell fates
toward specific cortical areas such as frontal or occipital cortex
or the cortical hem. For example, a recent study has shown
the derivation of cortical precursors enriched in hippocampal
granule neurons following exposure of cortical neuroepithelial
precursors to Wnt3a (Yu et al., 2014).
Interneurons
Cortical and striatal interneurons arise from the ganglionic
eminence, a ventral forebrain structure in the developing mam-
malian brain, and undergo tangential migration to reach their
appropriate targets (Anderson et al., 2001). hPSC-derived prim-
itive ground state neuroepithelium can be ventralized using Shh
agonists to induce robust NKX2.1 expression (Liu et al., 2013;
Maroof et al., 2013; Nicholas et al., 2013). Several classes of in-
terneurons and other ventral forebrain cell types (i.e., basal fore-
brain cholinergic neurons) may be generated by varying the
timing of Shh activation (Liu et al., 2013; Maroof et al., 2013).
Cortical interneurons initially display an immature GABAergic
phenotype and mature functionally over extended periods of
time in vitro and in vivo (Maroof et al., 2013; Nicholas et al.,
2013). It is currently unclear what percentage of hPSC-derived
interneurons correspond to striatal versus cortical interneurons
and the current protocols appear to generate primarily somato-
statin+ rather than parvalbumin+ interneurons. This is likely due
to the fact that parvalbumin expression occurs late at postnatal
stages of development and may not be detectable at the time of
analysis in most interneuron protocols. A recent protocol has re-
ported the derivation of interneurons enriched for a Calretinin+
fate suggesting a caudal ganglionic eminence origin of those
neurons (Nestor et al., 2014).
Dopamine Neurons
The generation of midbrain dopamine neurons for cell replace-
ment therapy in PD has been a longstanding goal. Accordingly,
several groups have reported the derivation of midbrain dopa-
mine neuron-like cells that were generated through a neuroepi-
thelial intermediate and the addition of Shh agonists and FGF8
(Perrier et al., 2004; Sonntag et al., 2007; Yan et al., 2005). How-
ever, these cells did not display all the cardinal features of
authentic mesencephalic dopamine (mesDA) neurons and did
not survive well after transplantation. In contrast, the stepwise
recapitulation of developmental processes, namely the genera-
tion of a midbrain floorplate intermediate by activation of Shh
signaling (Fasano et al., 2010) followed by their neurogenic
conversion through Wnt activation, ultimately produced cells
with transcriptional, biochemical, and physiological features of
bona fidemidbrain dopamine neurons (Kirkeby et al., 2012; Kriks
et al., 2011). These protocols have been validated by various in-
dependent groups (Doi et al., 2014; Sundberg et al., 2013; Xi
et al., 2012). A remaining challenge in the directed differentiationof midbrain dopamine neurons from hPSCs is the selective deri-
vation of substantia nigra (SN, A9) as opposed to ventral
tegmental area (VTA, A10) dopamine neurons. Despite claims
in some papers to selectively generate cells of A9 identity, formal
proof that this has been achieved remains pending. The main
challenge is the lack of specific early markers of A9 versus A10
subtypes. Current markers such as Calbindin (CALB1) for A10
or GIRK2 (KCNJ6) for A9 subtype identity do not appear to be
sufficiently specific to resolve cell identity at early stages of
dopamine neuron development. Therefore, functional studies
such as migration assays, axonal pathfinding assays (Cord
et al., 2010; Grealish et al., 2014), or careful physiological exper-
iments (Chan et al., 2010) will be required to validate A9 versus
A10 properties of grafted cells in vitro and in vivo. In addition,
expression profiling including single cell analysis as has been
done for rodent dopamine neurons (Panman et al., 2014; Poulin
et al., 2014) will be necessary to compare bona fide human fetal
ventral midbrain explants with their PSC-derived counterparts.
Motoneurons
Spinal motoneurons (MNs) are affected in several degenerative
neurological diseases (e.g., amyotrophic lateral sclerosis or
spinal muscular atrophy) as well as at the site of local damage
in spinal cord injury. Therefore, the generation of this cholinergic
neuronal cell type has been at the center of intense research ef-
forts since human pluripotent cells became available, reviewed
in Davis-Dusenbery et al. (2014). Similar to dopamine neurons,
spinal MNs can be generated in vitro from hPSCs through the
recapitulation of developmental signals. Neural induction initially
relied on EB formation (Boulting et al., 2011; Karumbayaram
et al., 2009; Li et al., 2005; Singh Roy et al., 2005) or co-culture
with neural inducing cells such as MS5 or PA6 (Lee et al.,
2007). The use of SMAD inhibitors for neuralization (Amoroso
et al., 2013; Patani et al., 2011) has simplified, accelerated and
boosted efficacy of spinal MN production (Boulting et al.,
2011). Most studies have relied on the use of high dose retinoic
acid (RA) for caudalization and Shh or one of its small molecule
agonists for ventralization of primitive neuroepithelium, resulting
in MNs with a mostly cervical/brachial HOX code. A combinato-
rial small molecule screening approach revealed the derivation of
cranial in addition to spinal MNs (Maury et al., 2015) and further
optimized yield. The recapitulation of MN diversity and subtype
specification within the spinal cord is however less well under-
stood. Reducing or eliminating RA treatment during MN induc-
tion can yield fates posterior to the brachial/cervical level though
at the expense of MN yield (Peljto et al., 2010). In addition, FGF
and Wnt signaling pathways have been reported to induce more
caudal MN fates (Mazzoni et al., 2013). However, those findings
are awaiting implementation in human cells. Also, recreating the
intricate columnar organization of MNs in the spinal cord, which
defines axonal projections to specific muscle groups, remains a
challenge to the directed differentiation field (Amoroso et al.,
2013; Patani et al., 2011).
Striatal Medium Spiny Neurons
Another neuronal cell type of great interest in regenerative med-
icine are neostriatal medium spiny projection neurons, which
degenerate in HD. A major motivating factor for the directed dif-
ferentiation of hPSCs intomedium spiny neurons are the ongoing
clinical trials in HD using human fetal tissue to replace functionalNeuron 86, April 8, 2015 ª2015 Elsevier Inc. 189
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ress has been made over the last few years starting with
feeder-based hPSC neuronal induction protocols and low dose
treatment with both Shh agonists and Wnt inhibitors (Aubry
et al., 2008). More recent refinements of this protocol have
improved efficiency and demonstrated the authentic nature
and in vivo potential of PSC-derivedmedium spiny neurons (Delli
Carri et al., 2013; Ma et al., 2012).
Oligodendrocytes
Significant progress has also been achieved regarding the gen-
eration of myelinating oligodendrocytes (Hu et al., 2009; Wang
et al., 2013). Oligodendrocytes have a broad potential in regen-
erativemedicine ranging from applications in spinal cord injury to
the use in various genetic, chemical, or radiation-induced demy-
elinating disorders (Goldman et al., 2012; Piao et al., 2015). The
guiding principles behind the generation of medium spiny neu-
rons and oligodendrocytes and their significance in regenerative
medicine have been discussed inmore detail recently (Tabar and
Studer, 2014).
Pluripotent Cell Sources
The prospect of generating patient-specific human pluripotent
cells (Takahashi et al., 2007) for regenerative therapies has
been hailed as a breakthrough on the road to personalized med-
icine. However, several scientific and economic considerations
make this a challenging approach to enter routine clinical use.
First of all, the timeframe and resources required to generate cur-
rent Good Manufacturing Practice (cGMP) quality autologous
iPSCs and differentiated transplantable progeny for every single
patient seem to preclude mass application with current technol-
ogy. An alternative could be the development of iPSC banks ho-
mozygous for major human leukocyte antigen (HLA) haplotypes,
which would serve as universal donors. This strategy could result
in the generation of about 150 iPSC or hESC lines with sufficient
homology to >90% of a population such as the UK (Turner et al.,
2013). While an attractive approach, there remains some contro-
versy regarding the immunogenicity of even syngenic iPSC-
derived transplants in mice, reviewed in Fu (2014). Furthermore,
the immunogenicity of human cells, whether autologous, HLA
matched, or unmatched, can only be inadequately assessed in
preclinical models, such as in mice with humanized immune sys-
tems. In one such study, reduced immunogenicity of unmatched
hESC-derived tissue has been reported (Drukker et al., 2006).
Also the need for autologous or matched donor cells, especially
for transplantation into the immunoprivileged CNS (Muldoon
et al., 2013), is not entirely clear. Early fetal grafting trials showed
that unmatched donor neurons survive for more than a decade
in patient brains after cessation of immunosuppression (Cooper
et al., 2009; Li et al., 2010). Nonetheless, clinical outcomes of
these trials were suboptimal, which could in part relate to chronic
inflammation or actual immune rejection of the graft (Barker
et al., 2013a). The acquisition of genetic and epigenetic alter-
ations occurs in any cultured cell type (Na¨rva¨ et al., 2010). How-
ever, reprogramming to pluripotency may confer an additional
risk (Pera, 2011). Lately, reprogramming to pluripotency has
also been achieved in human cells by somatic cell nuclear
transfer (SCNT) into oocytes (Tachibana et al., 2013; Yamada
et al., 2014). Genetic comparisons of iPSCs with isogenic
SCNT ESCs have produced contradictory results (Ma et al.,190 Neuron 86, April 8, 2015 ª2015 Elsevier Inc.2014). In a recent study, high-quality iPSCs generated by RNA
reprogramming showed similar frequencies of coding mutations
and loss of imprinting as SCNT ESCs (Johannesson et al., 2014).
Given all these variables, the optimal pluripotent cell source for
clinical translation remains to be determined.
Alternative Cell Sources and Direct Reprogramming
In addition to primary and pluripotent-derived cell types, there is
increasing interest in deriving specific neural cell types using
direct reprogramming approaches. The use of transcription fac-
tors to enforce ectopic cell fates in somatic cell types builds on a
long history of basic cell fate specification studies such as the
derivation of skeletal muscle cells from fibroblasts by MYOD1,
or the expression of CEBPA to convert pre-B cells or even fibro-
blasts into macrophages, reviewed in Graf and Enver (2009).
However, this approach has only received serious consideration
for regenerative medicine applications since the Wernig lab
demonstrated the efficient conversion of fibroblasts into func-
tional neurons both in mouse and human cells (Pang et al.,
2011; Vierbuchen et al., 2010). Subsequently, it was shown
that not only transcription factors but also microRNAs (miRNAs)
(Ambasudhan et al., 2011; Yoo et al., 2011) can induce new
cell fates. Several of the cell types discussed previously such
as midbrain dopamine neurons, MNs, oligodendrocytes, or
cortical-like neurons have been reported (Ang and Wernig,
2014). However, their therapeutic potential remains insufficiently
validated. Particular points of concern relate to the geneticmodi-
fication of the cells and the fact that these strategies often yield
postmitotic neurons with unclear scalability and engraftment
capabilities. In addition, it is also unclear how faithfully transdif-
ferentiated cells adopt the intended fate and how completely
the transcriptional program of the cell of origin is silenced. To
address this issue, a novel computational tool called CellNet
has been introduced (Morris et al., 2014). It allows users to quan-
titatively compare whether engineered cells are equivalent to
their primary target population with respect to gene expression.
Other cutting edge approaches in the field of cell fate conversion
include the cell fate switch of various cortical neuron subtypes
based on the increasing understanding of the transcriptional cir-
cuits underlying cell fate identity within the telencephalon (Ama-
moto andArlotta, 2014), and the conversion of endogenous brain
tissue into disease-relevant cells in vivo (De la Rossa et al., 2013;
Niu et al., 2013; Rouaux and Arlotta, 2013). While a fascinating
perspective, the therapeutic potential of this approach remains
to be determined. The need for the intracerebral injection of
viral vectors and the possibility of generating partially reprog-
rammed cells represent additional risks. Also, the strategy uti-
lizes resident cells, whose original function would likely be lost
after transdifferentiation with unclear consequences for host
brain function.
II. Efficacy in Preclinical Models
Therapeutic efficacy of human donor cells of various sources
(Figure 1A) is usually evaluated in animal models of neurological
disease. Given the protracted timeframe for functional matura-
tion of human cells, which resembles the timing of normal human
brain development, behavioral recovery of neurological function
may only be observed over the course of several months. The
putativemechanisms through which the graft induces behavioral
Figure 1. Mechanisms of Stem Cell-Based
Brain Repair
(A) Neural cells derived from pluripotent stem cells
(PSCs) as well as adult neural stem cells (NSCs)
and mesenchymal stem cells (MSCs) are used for
therapeutic purposes.
(B) Donor neuronsmay drive repair by neuronal cell
replacement and integration into host networks.
Network integration can be tested by optogenetic
or pharmacogenetic manipulation of the graft.
(C) Various neural and non-neural donor pop-
ulations may release therapeutic factors (such as
brain-derived neurotrophic factor [BDNF], glial cell
line-derived neurotrophic factor [GDNF], and
VEGF) to promote recovery in the host brain. Tro-
phic effects could be assessed using blocking
antibodies (black) or by engineering grafts, which
overexpress a candidate factor or are deficient
in it.
(D) Astroglial cells have been used for the delivery
of missing enzymes in metabolic disorders. The
effect of enzyme replacement can be assessed by
engineering grafts that overexpress an enzyme or
are deficient in it (e.g., ASA or PPT1).
(E) The immune response of the host (depicted in
red, e.g., T cell response, microglia, TNF, or interleukins) can be modulated by NSC as well as MSC transplantation. Factors mediating these effects are largely
unknown (?), but secretion of BMP4 and leukemia inhibitory factor (LIF) has been implicated.
(F) Transplanted oligodendrocytes have been shown to remyelinate endogenous axons. The effect of remyelination could be assessed by comparing the effect
with a non-myelinating graft. Donor cells are depicted in green. Proposed therapeutic mechanisms and experimental strategies to test for such mechanisms are
depicted in blue.
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mechanisms include actual neuronal integration and network
repair (Figure 1B), the provision of trophic support (Figure 1C),
enzyme replacement (Figure 1D), secretion of neuromodulators
and immunomodulation (Figure 1E), prevention of scar forma-
tion, and remyelination (Figure 1F). Moreover, it is conceivable
that several mechanisms work in combination to promote recov-
ery, while others may also be responsible for graft-induced
adverse effects. We therefore believe that a mechanistic under-
standing of the principles that underlie behavioral recovery is
necessary to evolve stem cell therapies into safe and effective
clinical therapies. In the following section we review the thera-
peutic benefits that have been reported with a special emphasis
on the mechanisms that have been proposed to drive recovery.
Primary NSCs
Human CNS stem cells (HuCNS-SCs) can be expanded in vitro
while maintaining the ability to generate neurons, astrocytes,
and oligodendrocytes (Uchida et al., 2000). Such cells have
shown beneficial effects in several animal models of neurological
diseases. For example, locomotor recovery was demonstrated
after spinal cord lesions in mice (Cummings et al., 2005; Salazar
et al., 2010). In these studies the multipotent cell population has
been shown to both remyelinate axons and form synapses onto
host neurons. The experimental design is noteworthy, since the
therapeutic effect was reversed by selective ablation of the graft.
This finding was among the first to provide clear evidence for the
functional integration of grafted cells into host circuits. However,
since the entire graft was ablated, this approach does not
prove whether the neuronal component, remyelination, both in
conjunction or something else was necessary to induce recov-
ery. In another application, the same cell population (HuCNS-
SCs) was found to slow neurodegeneration and motor decline
in an animal model of an infantile lysosomal storage disorder(Tamaki et al., 2009). After transplantation into newborn mice
harboring the disease, HuCNS-SCs migrated significantly and
expressed the missing enzyme. The neuroprotective effect is
believed to be dependent on enzyme substitution stemming
from human cells. Which cell type of the human neural lineage
may be most effective regarding enzyme substitution remains
unclear. However, forced overexpression of arylsufatase A
(ASA) in glial precursors transplanted into an animal model of a
different lysosomal disease conferred an additional benefit (Klein
et al., 2006). Regarding enzyme substitution, astrocytes may
appear as a preferred donor cell type since a therapeutic factor
could be distributed via gap junctions to the host. HuCNS-SCs
were also shown to promote recovery in stroke-lesioned rats.
The therapeutic benefit, which was found to occur in two tempo-
rally and mechanistically distinct waves, was attributed to stem
cell-mediated repair of the blood brain barrier, immunomodula-
tion as well as vascular endothelial growth factor (VEGF)-depen-
dent neovascularization (Horie et al., 2011). Importantly, the au-
thors showed that the effect on neovascularization was blocked
by a human-specific VEGF antibody, which is a rare demonstra-
tion of therapeutic specificity. In another application, HuCNS-
SCs were further shown to substantially remyelinate the CNS
of newborn and juvenile mice that lack endogenous myelin
(Uchida et al., 2012). Moreover, these cells have been shown
to protect photoreceptors and preserve retinal integrity in a rat
model of macular degeneration (McGill et al., 2012). Interest-
ingly, progeny of HuCNS-SCs of unclear fate targeted to the
subretinal space formed a cellular layer replacing defective
retinal pigment epithelium (RPE) and phagocytizing outer seg-
ments of photoreceptors (Cuenca et al., 2013). In summary,
HuCNS-SCs have been reported to generate therapeutic effects
in a variety of animal models with surprisingly diverse etiologies.
The proposed mechanisms comprise neuronal replacement,Neuron 86, April 8, 2015 ª2015 Elsevier Inc. 191
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vascularization, trophic support, and phagocytosis for this
particular donor cell population. This opens up the possibility
that the multipotent donor cell population undergoes differentia-
tion according to the needs of the diseased tissue. However, the
identity of the cell type conferring the benefit remains unclear in
most studies. This raises the concern that despite evidence of
therapeutic efficacy, the subset of HuCNS-SC progeny not
contributing to the therapeutic effect in a particular paradigm
may cause side effects, which could go unnoticed in preclinical
models. Furthermore, the lack of a clear mechanism raises con-
cerns about how to assess the potency of the cells and to define
an optimal cell dose in addition to defining risk related to poten-
tial side effects.
An additional human NSC line that has been shown to in-
duce substantial benefit is the fetal spinal cord derived line
NSI566RSC (Guo et al., 2011; Yan et al., 2007). A comprehensive
regenerative therapy for amyotrophic lateral sclerosis (ALS, Lou
Gehrig’s disease) may be difficult to conceive because cortical
and spinal MNs degenerate along the entire neuraxis. An ideal
therapy would therefore replace or protect cortical as well as spi-
nal neurons. In a first promising step, however, intraspinal trans-
plantation of NSI566RSCs in a genetic animal model of ALS has
been shown to preserve endogenous alpha-motoneurons near
the graft (Hefferan et al., 2012) and extend lifespan by approxi-
mately 2 weeks (Xu et al., 2011). The benefit is largely attributed
to NSC-dependent trophic effects, but formal proof regarding
the mechanism is pending. NSI566RSCs have also been tested
in a severe model of spinal cord injury alongside human ES and
iPS cells (discussed in the Spinal Cord Injury section below).
Immunomodulation
Over thepast decade thebi-directional interplay betweenendog-
enous or transplanted NSCs and the immune system has been
recognized, a subject discussed in detail in a recent review (Ko-
kaia et al., 2012). A direct immunomodulatory role of primarymul-
tipotent neural precursors has been demonstrated in murine
models of neuroinflammation (Pluchino et al., 2003, 2005) and
subsequently reproduced using human NSCs in non-human pri-
matemodels (Pluchinoet al., 2009a). Theneural stemcell-depen-
dent mechanisms providing immunomodulation are potentially
complex and remain largely unexplored. In some studies the
secretion ofBMP4 (Pluchinoet al., 2009b) and leukemia inhibitory
factor (Cao et al., 2011) from grafted NSCs have been proposed
as mechanisms to mediate immunomodulation via inhibition of
dendritic and T cell function. Beyond the action of NSCs in
primary inflammatory disease, immunomodulatory or neuropro-
tective effects may also play a role in the action of human stem/
progenitor cells in neurodegenerative disease such as in animal
models of PD (Redmond et al., 2007) or HD (McBride et al., 2004).
For most primary NSC populations, there is a limitation in scal-
ability due to telomere erosion and changes in fate potential
following long-term in vitro culture often resulting in cells with
increasing glial differentiation propensities. Those are challenges
for clinical translation that may limit clinical usefulness. Immortal-
ization has been proposed as a strategy to preserve the initial dif-
ferentiation potential, and the use of immortalized cells has been
proposed for several clinical applications (www.reneuron.com).
However, given the safety concerns associatedwith immortaliza-192 Neuron 86, April 8, 2015 ª2015 Elsevier Inc.tion and the availability of alternative strategies and cell sources,
such a strategy should only be pursued with the utmost caution.
Mesenchymal Stem Cells
Despite the fact that mesenchymal stem cells (MSCs) have
no known physiological function in the brain, a large body of pre-
clinical studies as well as initial clinical trials have reported bene-
ficial effects after MSC transplantation. MSC transplantation is
thought to act via trophic and immunomodulatory mechanisms,
whereas their potential for cell replacement remains controver-
sial. Findings and perspectives regarding the use of MSCs in
neurological diseases are the topics of several recent review ar-
ticles (Uccelli et al., 2011; Wan et al., 2014).
Neural Cells Derived from PSCs
As outlined in Generation of Neural Cell Types from Various
Sources, specialized cell types have been generated from
PSCs. In most cases, donor cells for therapeutic applications
are pre-differentiated in vitro but injected into adequate animal
models before the donor cell type reaches a fully mature
status. Also, most donor cell populations are not pure even if
enriched by means of cell sorting. They usually contain minority
fractions of other neuronal populations and often astroglial
precursors.
RPE for the Treatment of Macular Degeneration
RPE has been successfully generated from hPSCs, reviewed
in Ramsden et al. (2013). To assess efficacy, ES-derived
RPE has been injected into the subretinal space of royal
college of surgeon (RCS) rats, which develop a genetic form of
macular degeneration. Notably, the preservation of photorecep-
tors, physiologic retinal activity and the improvement of visual
performance were shown in a number of studies (Lu et al.,
2009; Vugler et al., 2008; Zhu et al., 2013). It is particularly
encouraging that PSC-derived RPE recapitulates bona-fide
RPEmorphology, phagocytoses photoreceptor outer segments,
and cycles retinol. PSC-derived RPE transplanted into immuno-
deficient mice also shows a favorable long-term safety profile
(i.e., no teratoma formation or other type of overgrowth).
Dopamine Neurons for Use in PD Cell Therapy
The therapeutic efficacy of donor cell populations for PD is usu-
ally assessed in a chemical lesion model in rodents (Grealish
et al., 2010) where 6-hydroxydopamine is used to ablate the
endogenous dopaminergic innervation unilaterally in the dorsal
striatum. Transplantation of hPSC-derived dopamine neurons
into the denervated striatum (Kirkeby et al., 2012; Kriks et al.,
2011) (i.e., ectopic transplantation) or potentially the midbrain
(Grealish et al., 2014) reverses the resulting motor asymmetry in
various behavioral tests. Prevailing thought holds that such
grafted dopamine neurons extend fibers into the denervated
striatum, form synaptic connections with resident medium spiny
striatal projection neurons, mature physiologically over the
course of several months, and ultimately start to release dopa-
mine resulting in circuit repair and behavioral recovery. This
view is supported by one study showing that re-lesioning ablates
recovery (Dunnett et al., 1988). However, chemical re-lesioning
of the dopaminergic system ablates all dopamine neurons, in-
cluding any recovering host dopamine fibers. Additional support
for the idea to prefer bona-fide midbrain dopamine neurons as
donor source comes from studies showing that non-dopamine
neural transplants cannot induce behavioral recovery (Cenci
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however, since other cell populations like GABAergic interneu-
rons (Martı´nez-Cerden˜o et al., 2010), growth factor releasing as-
trocytes (Proschel et al., 2014), and even MSCs (Glavaski-Joksi-
movic et al., 2010) have been proposed to induce at least partial
recovery. Also, current protocols do not yield pure midbrain
dopamine neurons, and it is unclear whether pure dopamine
graftswould confer and additional benefit. Similar to early studies
utilizing fetal tissue, PSC-derived dopaminergic cultures contain
at least serotonergic andGABAergic contaminants aswell as glial
precursors. The role of theseadditional populations regarding the
induction of a therapeutic benefit remains poorly understood.
The presence of serotonergic neurons is particularly troubling
since graft-induced dyskinesias that were observed in clinical tri-
als have been linked to serotonergic contaminants (Politis et al.,
2010). Nonetheless, the robustness of recovery in preclinical
models is encouraging. Therefore, a thorough understanding of
graft function and connectivity and the elimination of contami-
nants through cell sorting strategies should contribute to the gen-
eration of a standardized PSC-derived cell product on the road
toward clinical application.
Cortical Neurons for the Treatment of Experimental
Stroke
Cortical neurons have also been specified from an iPSC-derived,
highly neurogenic NSC population and tested in a rat stroke
model (Tornero et al., 2013). In contrast to the study employing
HuCNS-SCs (Horie et al., 2011), this study focused on the poten-
tial of neuronal cell replacement. Cortical neurons were targeted
to the ischemic rat cortex and found to differentiate and function
physiologically according to their pre-specified fate. Axonal
outgrowth waswidespread andmainly along whitematter tracts.
Behaviorally, animals showed a modest recovery, which was
correlated with the presence of the graft. Which aspect of graft
function causes behavioral recovery, e.g., neuronal function
and integration or the previously proposed mechanisms such
as repair of the blood brain barrier, immunomodulation, neovas-
cularization or a complex combination thereof, remains unclear.
Interneurons for Modulating Excitability and Plasticity
The rationale for the application of interneurons in neurological
disease has recently been reviewed (Southwell et al., 2014). In-
terneurons have shown beneficial effects in a number of animal
models of disorders associated with an imbalance between
excitation and inhibition of neuronal networks (e.g., epilepsy,
schizophrenia, or autism). Of particular interest is also their
migratory capacity, which could be utilized for the widespread
delivery of therapeutic agents (Liu et al., 2013; Maroof et al.,
2013; Nicholas et al., 2013). Protracted functional maturation
of these neurons, which reflects ontogeny, may impose sig-
nificant experimental challenges. For example hPSC-derived
interneurons grafted into neonatal hosts retained highly imma-
ture properties even 7 months after transplantation (Nicholas
et al., 2013). Nonetheless, one recent study showed potent
seizure suppression and amelioration of associated behavioral
abnormalities even before full electrophysiological maturation
in a temporal lobe epilepsy model (Cunningham et al., 2014).
A different group described a therapeutic benefit, of a popula-
tion containing interneurons and basal forebrain cholinergic
neurons. It was shown to correct a memory deficit induced bysepto-hippocampal lesioning. The benefit was specific to the
ventral forebrain population as opposed to a spinal cord
GABAergic population, but the study was not designed to clarify
the therapeutic mechanism in more detail (Liu et al., 2013).
Spinal Cord Injury
In spinal cord injury the lesion pattern is complex involving
destruction of spinal MNs and local interneurons at the site of
injury as well as discontinuation ofmyelinated axons transmitting
information from the brain to the spinal cord and vice versa.
Therefore, several cell types may contribute to functional recov-
ery through a variety of mechanisms (Lu et al., 2014a). hESC-
derived oligodendrocytes were demonstrated to remyelinate
spared axons and restore locomotion in a model of incomplete
(compression) spinal cord injury (Keirstead et al., 2005). Recently
established, myelin-defective iPSC-derived oligodendrocytes
(Numasawa-Kuroiwa et al., 2014) could now be used to assess
the extent towhichmyelination versus different donor cell depen-
dentmechanisms contribute to recovery. Alternative approaches
have focused on the introduction of NSCs to bridge the site of
injury and reconnect the distal and the proximal ends at the lesion
site. Dramatic findings were reported when Lu et al. (2012)
embedded human NSI566RSCs and ESC-derived NSCs into a
fibrin and growth factor matrix. The matrix served to bridge the
lesion cavity caused by complete T3 transsection and supported
the survival and differentiation of donor cells. Axonal outgrowth
extended several centimeters in rostral and caudal directions
into the injured spinal cord and significantly restored locomotion.
In a follow-up study, human iPSC-derived neural precursor cells
were grafted into C5 lateral spinal cord lesions (Lu et al., 2014b).
Axonal outgrowth extended over the entire length of the rat CNS.
However, locomotion did not recover, which may be due to the
majority of grafts showing central collagen-rich rifts or insufficient
behavioral follow-up, which was terminated at 3 months. None-
theless, these findings are altogether very encouraging since
they indicate that humanNSCsmaybe able to functionally recon-
nect the severely lesioned spinal cord.
Restorative Approaches for the PyramidalMotor System
The functional reconstruction of the pyramidal motor system
spanning from the motor cortex via the cortico-spinal tract
(CST), the lower MNs in the ventral horn to the skeletal muscle,
has been a challenging and longstanding goal. If accomplished,
such an approach could contribute to the restoration of motor
function in a number of disease paradigms (e.g., stroke, ALS,
spinal cord injury). Encouraging results were reported when ho-
motopic mouse E14 cortical tissue blocks were grafted into the
acutely lesioned adult mouse sensori-motor cortex (Gaillard
et al., 2007). Transplants integrated well into cortical lesions
and axonal outgrowth reached appropriate cortical, subcortical,
and spinal cord targets. Unfortunately, the behavioral conse-
quences of lesioning and grafting were not assessed; therefore,
also the functional connectivity of these transplants remains
unclear. The embryonic, homotopic nature and organotypic
preservation of the graft were believed to be the determinants
of successful axonal pathfinding in this study. However, signifi-
cant axonal outgrowth from cortical transplants to cortical,
subcortical, and cervical spinal cord targets has also been re-
ported after transplantation of hESC-derived NSCs (Steinbeck
et al., 2012). CST terminals synapse onto lower spinal cordNeuron 86, April 8, 2015 ª2015 Elsevier Inc. 193
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to the success in generating hPSC-derived spinal MNs, several
studies have evaluated their intraspinal engraftment. Human
MNs can engraft in the spinal cord and axons project into the
ventral root of embryonic chick (Amoroso et al., 2013; Lee
et al., 2007) and adult rodent hosts (Lee et al., 2007). Efficient
engraftment and axonal projections into the ventral root were
also observed after transplantation of NSI566RSCs (Yan et al.,
2007) into nude rats. Apart from survival and choosing the appro-
priate trajectory, grafted MNs would have to innervate skeletal
muscle and receive cortical inputs to restore connectivity. In
consideration of the distance between the spinal cord and limb
and lacking guidance cues in the adult host, this is an enormous
challenge, which despite extensive efforts (Deshpande et al.,
2006) has not yet been resolved in a relevant animal model. How-
ever, mouse ESC-derived spinal MNs directly injected into the
lesioned sciatic nerve were shown to functionally connect to
limb muscles in vivo (Bryson et al., 2014).
General Safety Considerations
Major determinants of the safety profile are related to the sterility
of the cell source, the delivery of the cells to the CNS, and the
long-term proliferative capacity of the donor cell population. In-
jection of donor cells into various regions of the brain and spinal
cord has been optimized and can be performed safely (see Clin-
ical Trials). Intra-operative MRI also allows real-time monitoring
of stereotactic injections, which should further increase accuracy
and safety (Larson et al., 2012). With regard to the proliferative
potential of the donor population, primary cells have the principle
advantage that they do not contain pluripotent contaminants,
which harbor the potential for teratoma formation. Nevertheless,
tumors arising from clinical transplantation of primary NSCs have
been described (Amariglio et al., 2009) though the exact nature of
the cells engrafted in this study remains unclear. Potentially
oncogenic genetic alterations can occur in any cultured cell
type. Therefore, close monitoring of genetic integrity is manda-
tory for any donor cell population awaiting clinical application.
Integration of suicide genes (Di Stasi et al., 2011) into genomic
safe harbors (Papapetrou et al., 2011) has been proposed as a
strategy to ablate a graft in case it produces intolerable effects
as reviewed in detail elsewhere (Kiuru et al., 2009; Lee et al.,
2013). The long-term proliferative potential of a donor cell popu-
lation is also dependent on its maturation status at the time of
transplantation. Efficient pre-differentiation of pluripotent donor
cells toward the desired fate greatly reduces the risk of teratoma
formation or unwanted overproliferation of cells resisting final
differentiation. Such differentiation strategies can be based on
the exposure to extrinsic cues (Chambers et al., 2009) or to
intrinsic factors such as neurogenic transcription factors that
can drive neuronal fates to near purity (Zhang et al., 2013). How-
ever, the capabilities for successful engraftment and integration
of donor cells may decline with increasing maturity at the time
of engraftment. Inmany neuron replacement paradigms, neurons
at the stage of cell cycle exit (e.g., neuroblasts) are regarded as
a reasonable compromise to ensure cell type specificity and
integration while reducing the risk of tumor formation (Kriks
et al., 2011; Liu et al., 2013). However, the specific safety con-
cerns have to be assessed individually for each candidate cell
population. Beyond the risk of overproliferation and tumor forma-194 Neuron 86, April 8, 2015 ª2015 Elsevier Inc.tion, grafts may exhibit the risk of aberrant host innervation,
ectopic distribution of cells outside the target area, immune-
rejection, and CNS inflammation among others. Several of these
caveats may remain unnoticed in preclinical studies. Therefore,
the clinical translation of candidate populations must be con-
ducted under closely monitored clinical trial conditions.
III. Derivation of Donor Cells under cGMP Conditions
Once efficacy is proven in a preclinical model and before a
clinical trial may be initiated, the donor cell population has to
be produced under clinical-grade standards. In the United
States, cGMP regulations are enforced by the Food and Drug
Administration (FDA) and comprise standard operating proce-
dures for manufacturing and quality control in a dedicated facil-
ity. This is not a trivial matter sincemost cell lines used in preclin-
ical studies were not initially derived under cGMP standards.
New human pluripotent cell lines have therefore been derived
and banked under cGMP conditions (Crook et al., 2007; Tannen-
baum et al., 2012). In the United States, this process includes the
derivation of the cells from tested, traceable donors and replace-
ment of all animal products, i.e., feeder cells, serum, growth fac-
tors, enzymes for passaging, and extracellular matrices. It is
interesting to note that some regulatory bodies accept animal
components and therefore the process in such countries will
differ from the US process; even within the United States, not
all cell products that move into early stage clinical trials are
xeno free (see below). Several non-cGMP cell lines have been
transferred into cGMP facilities, which requires propagation
and expansion of the line for several passages along with exten-
sive testing for adventitious pathogens (Durruthy-Durruthy et al.,
2014) (www.gmpbio.org). Cell lines should be generated and
maintained in a clean room and have to be monitored for main-
tenance of the correct karyotype, identity, and sterility. The
transition to cGMP-qualified cell lines; animal-free, cGMP plurip-
otent culture systems; and the substitution of non-cGMP com-
pliant components of the differentiation protocol represent
frequent challenges in the transition from preclinical to clinical
studies. In some cases, cGMP reagents do not exist and in
others the cost to manufacture custom batches is prohibitive.
Likewise, many processes can be qualified in the early stages
of clinical trials. The process of qualification means presenting
the regulatory authorities with as much information as possible
about purity, processing, raw ingredients, sterility, etc. For
each reagent, risk mitigation is a top priority for scientists and
regulators. A ‘‘clean’’ reagent that creates a less potent product
might create greater risk for a patient. As such, some of the early
groups that treated patients with hESC-derived cells have
decided to maintain their hESCs on mouse feeder cells
(Schwartz et al., 2012). The mouse feeders used had to be
derived under cGMP conditions and were subject to the normal
extensive battery of tests used for any cGMP cell bank. Such
concessions are often made during the early phases of a clinical
trial but are expected to be less likely as a treatment approaches
to become a commercial product.
IV. Clinical Trials
The success in inducing behavioral recovery in several preclinical
paradigms led to the initiation of clinical studies using these
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phase I clinical study that pioneered the transplantation of their
NSI566RSC spinal cord derived stem cells into the lumbar spinal
cord of ALS patients, reporting no significant adverse effects
(Glass et al., 2012). A dose escalation phase II trial has been initi-
ated (www.clinicaltrials.gov, NCT01730716). NSI566RSC phase
I clinical trials are currently ongoing for chronic complete spinal
cord injury (www.clinicaltrials.gov, NCT01772810) and acute spi-
nal cord injury in Korea. For the treatment of chronic motor resi-
dues after ischemic stroke, a combined phase I/II clinical trial
was initiated in China in 2013. Efforts regarding the clinical trans-
lation of HuCNS-SCs by StemCells, Inc. have been recently re-
viewed (Tsukamoto et al., 2013). Phase I clinical trials have
been completed for an infantile lysosomal storage disorder (Sel-
den et al., 2013) and amyelination disorder (Gupta et al., 2012) re-
porting a favorable safety profile. Phase I trials are ongoing for
cervical and thoracic spinal cord injury (www.clinicaltrials.gov,
NCT02163876 and NCT01321333) and age-related macular
degeneration (www.clinicaltrials.gov, NCT01632527). The first
hESC-derived products developed for clinical application were
oligodendrocyte precursors intended to remyelinate spinal cord
lesions. After overcoming substantial regulatory hurdles and sig-
nificant delays, five patients were treated before Geron aban-
doned the trial for strategic and financial reasons (Frantz, 2012).
The patients are still being followed with an initial report of ‘‘no
serious adverse events related to AST-OPC1 administration’’
presented at the American Society of Gene & Cell Therapy
(ASGCT) meeting in 2014 (http://asteriasbiotherapeutics.com/
wp-content/uploads/2014/05/Lebkowski-ASGCT-5-22-14.pdf).
Asterias Biopharmaceuticals took over the portfolio from Geron
and recently received FDA clearance and $14.3 million from
CIRM (California Institute of Regenerative Medicine) to initiate a
Phase 1/2a clinical trial including dose escalation in 2015.
hESC-derived RPE is currently in phase I/II clinical trials in pa-
tients with macular degeneration. The first report of two treated
patients showed no significant adverse effects and possible
improvement in visual parameters (Schwartz et al., 2012) with a
recent follow-up report indicating therapeutic efficacy (Schwartz
et al., 2015). There is also renewed interest in the grafting of fetal
tissue for PD under optimized conditions in Europe (www.
transeuro.org.uk) (Barker et al., 2013a) in preparation for pluripo-
tent-derived dopamine neuron grafts being planned in the United
States, Japan, andSweden (GForce-PD.com). Significant further
challenges for the implementation of restorative therapies relate
to the internationally diverse regulatory requirements (Andrews
et al., 2014). Despite the considerable progress in translating
neural and pluripotent-derived products for early stage trials in
patients with neurological disorders, there is a remarkable
paucity of information regarding the specific mechanisms by
which those cells are thought to provide therapeutic benefit.
V. Current Strategies for the Enhancement of Structural
Integration
The structural integration of donor neurons into diseased brain
tissue is a key challenge for any therapy aimed at actual cell
replacement. Several aspects related to the structural integra-
tion of donor neurons (i.e., maturity, migration, axonal outgrowth)
have been the focus of recent studies (Figure 2).Donor Cell Maturity
One important question is how donor cell maturity affects sur-
vival, migration, axonal outgrowth, and ultimately therapeutic
efficacy. This question was systematically addressed by purify-
ing developmentally early Hes5+ midbrain precursors, midstage
Nurr1+ neuroblasts, and Pitx3+ mature neurons derived from
murine ESCs (Figure 2A). Each population was subsequently
transplanted into Parkinsonian mice to compare the in vivo ther-
apeutic potential (Ganat et al., 2012). The results show that
dopamine neuron survival and therapeutic efficacy was particu-
larly high in the donor cell population selected at the Nurr1+
neuroblast stage. Those cells are at an intermediate stage of dif-
ferentiation with high specificity for midbrain dopamine neuron
phenotype but retain sufficient developmental plasticity for func-
tional integration. Future studies are required to further test the
contribution of non-dopamine neuron subtypes in PD grafting
studies and to apply similar stage-specific transplantation para-
digms to other models of neurological disease.
Migration
The migratory capacity of donor cells is another aspect that can
greatly affect the regenerative potential. The ability of trans-
planted cells to migrate varies substantially, depending on the
developmental age (Wang et al., 2013) and region (Tabar et al.,
2005) of the host CNS. Most neural donor cell populations how-
ever show little, if any, migration if transplanted into the adult or
diseased CNS (Kriks et al., 2011; Steinbeck et al., 2012) unless
they represent a cell type with a particular migratory capacity
(Maroof et al., 2013; Nicholas et al., 2013). The restricted migra-
tory potential of most populations may limit therapeutic efficacy
where a widespread distribution of donor neurons or delivery of a
therapeutic factor is desirable (Li et al., 2007). Results from a
recent study demonstrate that the restricted migratory potential
of a NSC population may be enhanced (Ladewig et al.,
2014). The work showed evidence for chemoattraction between
NSCs and their differentiating progeny that prevents neuroblasts
from migrating into host tissue (Figure 2B). Purification of post-
mitotic neuroblasts before transplantation or pharmacological
inhibition of the chemoattraction between neurons and NSCs re-
sulted in enhanced migration. It remains to be shown, however,
whether such enhanced migration may indeed be beneficial in
the context of a therapeutic paradigm.
Axonal Outgrowth
Another possibility to increase tissue integration of a transplant is
to enhance its axonal outgrowth. This strategy was pursued
recently by increasing polysialic acid (PSA) in mouse ESC-
derived neural precursors via transgenic expression of the
polysialyltransferase (PST) enzyme. PSA, if added to the neural
cell adhesion molecule (PSA-NCAM) reduces inhibitory cell-cell
interactions by changing biophysical membrane properties,
thereby facilitating migration and axonal growth (Rutishauser,
2008). Overexpression of PSA in dopamine precursors signifi-
cantly increased axonal growth of tyrosine hydroxylase positive
fibers into the dopamine-depleted striatum, which was corre-
lated with more efficient amelioration of the Parkinsonian pheno-
type in these animals (Battista et al., 2014) (Figure 2C). In a related
approach, spinal motoneuron precursors overexpressing PSA
transplanted into the lesioned sciatic nerve extended axons
in higher numbers toward the denervated muscle (El MaaroufNeuron 86, April 8, 2015 ª2015 Elsevier Inc. 195
Figure 2. Strategies to Enhance Structural Integration
(A) Grafts of developmentally distinct dopaminergic populations were compared. Transplantations (TX) of neural precursors, neuroblasts, and mature neurons
varied with respect to survival and dopamine neuron content.
(B) Mixed grafts of NSCs (gray) and neuroblasts (green) form clusters, whereas pure neuroblasts migrated into the host brain. In mixed grafts, chemoattraction of
neuroblasts to NSCs can be overcome by blocking FGF and VEGF pathways.
(C) Axonal outgrowth into the host brain and therapeutic efficacy can be enhanced by expression of polysialyltransferase in grafted neurons.
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that does not require the genetic manipulation of the target cell
and relies on direct exposure of purified enzyme and substrate,
a technology suitable for increasing PSA in various cell types
and tissues (El Maarouf et al., 2012).
As an alternative to manipulating the cells to be grafted, ap-
proaches have been developed for rendering the host brain
more permissive for donor cell migration or axonal outgrowth.
PSA overexpression in astrocytes has been shown to enhance
endogenous axonal regeneration in a model of spinal cord injury
and facilitate recruitment of endogenous progenitors to a cortical
lesion site (El Maarouf et al., 2006). The external, non-genetic
addition of PSA not only to donor cells but also in vivo to host tis-
sue provides an interesting perspective. Co-injection of a donor
cell population with the PSA producing enzyme and its substrate
(El Maarouf et al., 2012) may result in optimized polysialylation of
donor and host and therefore superior tissue integration of
grafted cells. Other inhibitory constituents of the extracellular
matrix have been targeted as well. For example, growth-inhibi-
tory chondroitin sulfate proteoglycans (CSPGs) are upregulated
in spinal cord lesions and can be degraded by intraspinal deliv-
ery of chondroitinase ABC (C-ABC), which induces endogenous
axonal regeneration and behavioral recovery (Busch and Silver,
2007). When C-ABC treatment of a spinal cord lesion was com-
binedwith aNSC graft, migration of donor cells, aswell as axonal196 Neuron 86, April 8, 2015 ª2015 Elsevier Inc.integration into the lesioned spinal cord was enhanced (Ikegami
et al., 2005). Interestingly the growth promoting effect of C-ABC
is not restricted to the spinal cord. In rats with nigro-striatal tract
axotomies, C-ABC infusion resulted in the re-growth of the nigro-
striatal tract into its correct striatal target region (Moon et al.,
2001). Furthermore, mechanistically distinct growth promoting
strategies can be combined to achieve optimized outcomes
(Fouad et al., 2005; Zhao et al., 2013). However, most of these
growth-promoting strategies have not yet been explored in the
context of stem cell grafts.
Biomaterials
The use of biomaterials has been implemented for conditions
where the disease process produces large lesion cavities. A
degradable biomaterial scaffold could be combined with extra-
cellular matrix proteins, growth factors, and potentially drugs in
addition to the seeded donor cells (Orive et al., 2009). The goal
of such technologies is to create a microenvironment that facili-
tates the regenerative process. Such scaffolds have also proven
useful in supporting regenerative responses of the surrounding
brain tissue as it provides a substrate for host cell infiltration
and axonal outgrowth. Several studies employing donor cells
in scaffolds are particularly noteworthy. Large ischemia-induced
telencephalic lesion cavities were successfully re-populated by
mouse NSCs seeded onto polyglycolic acid biodegradable poly-
mers (Park et al., 2002). Axonal outgrowth from the graft as well
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robust and apparently specific over long distances. The second
study employed rat and human NSCs in a fibrin matrix, as has
been discussed for spinal cord lesions (Lu et al., 2012). An
example where biomaterials are in use to assure proper struc-
tural organization is the in vitro generation of transplantable hu-
man RPE. RPEs, if transplanted in a pre-specified monolayer
(as opposed to a cell suspension), may display enhanced func-
tionality and efficacy in animal models of macular degeneration
(Stanzel et al., 2014; Subrizi et al., 2012).
VI. Emerging Approaches for the Assessment of Graft
Function and Connectivity
The therapeutic potential of human cells is commonly assessed
using long-term behavioral assays following transplantation into
a relevant animal model of neurological disease (Kriks et al.,
2011; Liu et al., 2013; Steinbeck et al., 2015). However, such ex-
periments do not necessarily define the biological mechanisms
responsible for behavioral recovery.
Optogenetics and Pharmacogenetics
The goal of neuronal cell replacement or graft-mediated neuronal
network repair (Figure 1B) is often implied as a therapeutic ratio-
nale, but this concept remains insufficiently validated. It is clear
that human neurons functionally mature, generate action poten-
tials in vivo, and receive synaptic input from the host (Koch et al.,
2009; Tornero et al., 2013). Whether donor neurons are however
also able to relay information to the host and whether such func-
tional graft-to-host connectivity may be responsible for graft-
induced therapeutic benefits has been difficult to assess. Initial
strategies to address this issue sought to selectively ablate the
graft via the expression of diphtheria toxin in transplanted cells
(Cummings et al., 2005) or via chemical re-lesioning (Dunnett
et al., 1988). However, those approaches lead to a complete
elimination of the transplanted cellswithout addressing a specific
mechanism. In contrast, two new techniques, optogenetics
(Zhang et al., 2011) and pharmacogenetics (Rogan and Roth,
2011), allow the reversible functional manipulation of genetically
and spatially defined neurons with unprecedented precision. In
the case of optogenetics, light-sensitive ion channels or pumps
(opsins) are expressed in the cell population to be studied. De-
pending on the properties of the opsin, neurons can be activated
or silenced by exposure to light within milliseconds in vitro and
in vivo. Pharmacogenetic strategies depend on the expression
of a designer receptor exclusively activated by a designer drug
(DREADD). Such DREADDs are coupled to inhibitory or excit-
atory G-proteins, which activate or silence the neuronal popula-
tion expressing the receptor upon binding of the designer drug.
Optogenetics offers considerable advantages because of its
exquisite temporal resolution, which is required for many physio-
logical experiments. Pharmacogenetic strategies are in contrast
less invasive and enable the manipulation of larger tissue vol-
umes. Regardless of the technology, functional control of spe-
cific neuronal populations can link network activity to behavior
in freely moving animals in real time, including animals with
neurological disease (Chaudhury et al., 2013; Kravitz et al.,
2010). Despite the transformative role of optogenetics and
pharmacogenetics in neuroscience, these technologies are
only starting to impact our understanding of graft function andconnectivity. Some of the reasons for the slow adoption may
relate to the fact that hPSC-derived neurons require several
months for functional maturation (Johnson et al., 2007). The first
report showed that matured hESC-derived neurons expressing
Channelrhodopsin 2 (ChR2) reliably fire action potentials upon
every light pulse and that such controlled activity induces post-
synaptic responses in nearby ChR2-negative neurons in vitro
andafter transplantation (Weick et al., 2010). In follow-up studies,
ChR2-expressing human neurons were shown to modulate the
activity of mouse cortical networks in vitro (Weick et al., 2011)
and of organotypic rat hippocampal slices upon light activation
(Pina-Crespo et al., 2012). For the interpretation of many xeno-
grafting studies, this is essential information, since it proves
that human neurons can efficiently modulate the activity of a ro-
dent network. Exciting results that unequivocally demonstrated
the usefulness of optogenetics to analyze graft-to-host connec-
tivity in a behavioral regenerative paradigm were reported
recently. ChR2 expressing spinal MNs derived from murine ES
cells were implanted into the crushed sciatic nerve (Bryson
et al., 2014). After re-growth of donor axons into lower limb mus-
cles, light activation of the graft induced muscle twitches
(Figure 3A). Two studies addressed the function of transplanted
dopamine neurons in an animal model of PD (Figure 3B). In a
pharmacogenetic approach, murine induced dopamine neurons
(iDA) activated via a DREADD receptor during behavioral testing
generated an additional behavioral improvement (Dell’Anno
et al., 2014). We recently reported that optogenetic silencing of
tonically active hESC-derived dopaminergic grafts re-introduced
the pre-transplantation behavioral deficit, mimicking the effect of
chemical re-lesioning (Dunnett et al., 1988). We also provide
evidence that optogenetic graft silencing modulates the endog-
enous glutamatergic transmission onto host medium spiny
neurons in a manner reminiscent of the function of endogenous
substantia nigra mesDA neurons, which are lost in PD (Steinbeck
et al., 2015). However, the implications of these tools for regener-
ative medicine are even broader. The function of newly formed
endogenous connections, which emerged in the spinal cord after
degeneration of the corticospinal tract, has also been tested
(Figure 3C). DREADD-mediated inactivation of the new connec-
tions resulted in a dramatic loss of previously recovered forelimb
use (Wahl et al., 2014). Together, these studies demonstrate that
the application of optogenetic or pharmacogenetic strategies in
regenerative paradigms can establish the causative link between
grafting, behavioral recovery, and histological analysis. These
technologies therefore enable the clarification of mechanisms
that induce recovery in animal models of neurological disease.
Accordingly, we predict that the selective manipulation of graft
function will be instrumental in understanding and refining thera-
peutic approaches in many more disease paradigms and in
much greater detail. New generations of spectrally optimized op-
togenetic tools with enhanced light sensitivity (Berndt et al.,
2014; Chuong et al., 2014; Wietek et al., 2014) should facilitate
in vivo applications in a broader set of regenerative medicine
paradigms.
Optogenetics and pharmacogenetics are not limited to study-
ing graft function in behavioral experiments. Optogenetics in
particular has proven extremely useful in analyzing the connec-
tivity of a brain region in physiological experiments. In suchNeuron 86, April 8, 2015 ª2015 Elsevier Inc. 197
Figure 3. Strategies to Assess Neuronal Graft-to-Host Connectivity
For functional experiments, optogenetic or pharmacogenetic strategies have been used to stimulate (blue) or silence (orange) donor cells after recovery in
behavioral experiments. The initial lesion is depicted in red and the regenerative mechanism in green.
(A) Spinal motoneurons were injected into the crushed sciatic nerve of mice and donor axons reconnected to limb muscles. Blue light optogenetic stimulation of
the graft induced muscle contractions in the leg.
(B) In a Parkinson’s disease (PD) model with unilateral lesions, dopamine (DA) grafts correct the movement asymmetry. Pharmacogenetic graft stimulation
enhances recovery, whereas optogenetic graft silencing re-introduces the previous deficit, mimicking the effect of chemical re-lesioning of the graft.
(C) Rats with unilateral cortico-spinal tract (CST) lesions were subjected to a combination therapy to enhance axonal sprouting (green) from the contralateral CST.
This therapy induced motor recovery in the impaired paw. Pharmacogenetic silencing of the new connection resulted in muscle paralysis, demonstrating that
axonal sprouting from the healthy CST drives recovery.
(D) Grafted neurons infected with a GFP-tagged rabies virus transfer rabies-GFP (green) to presynaptic host neurons in vivo, thereby revealing the upstream
functional connectome of the graft.
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Reviewexperiments the brain region under study (potentially a graft)
is stimulated optogenetically while activity is assessed in the
expected target region, such as shown recently for human
GABAergic interneurons transplanted into the epileptic hippo-
campus (Cunningham et al., 2014). To date, the readout in
connected brain regions still depends largely on patch clamp
physiological measurements, which are time consuming. Also,
unexpected connections may go unnoticed, since researchers
may concentrate on one or two target regions in which they
expect to find connectivity. In contrast, functional imaging
strategies, which are becoming more andmore powerful, should
allow a more integrative assessment of the functional connec-
tome of stem cell grafts and the brain in general, which could
feedback into transplantation paradigms. Calcium imaging
has been used for the assessment of neural network dynamics
in vitro and in vivo for several decades (Grienberger and Kon-198 Neuron 86, April 8, 2015 ª2015 Elsevier Inc.nerth, 2012). Recent developments include the ability to image
assemblies of neurons in vivo in freely moving animals using
head-fixed miniature microscopes (Flusberg et al., 2008; Ghosh
et al., 2011; Sawinski et al., 2009). Also, genetically encoded cal-
cium indicators have been engineered to reliably achieve single
spike resolution (Chen et al., 2013; Thestrup et al., 2014). There-
fore, calcium imaging should be a suitable tool to image the ac-
tivity of both grafts and functionally connected neurons in vivo
and in slice preparations. Similarly, new types of engineered op-
tical voltage sensors (Cao et al., 2013; Hochbaum et al., 2014)
have recently been shown to faithfully report action potentials.
When combined with optogenetic stimulation, separation of
the light stimulus from the optical readout is crucial. This separa-
tion can be spatial, temporal, or spectral. The pairing of a bright
and fast voltage sensor with a spectrally non-overlapping
activating opsin has been reported, representing an all-optical
Neuron
Reviewsystem for simultaneous stimulation and readout. The activity of
dozens of neurons was recorded simultaneously and linked to
the activity of the stimulated population (Hochbaum et al.,
2014) in vitro. Using this technology, one could optogenetically
stimulate a graft and at the same time record neuronal activity
in the host brain in a slice preparation. Such experiments should
not only define the functional connectome of stem cell grafts
in the healthy or diseased brain but also make graft-to-host
connectivity amenable to pharmacological interrogation. While
experiments using genetically encoded voltage or calcium indi-
cators offer single neuron resolution, they will likely remain
restricted to slice preparations or imaging of neuronal assem-
blies near the brain surface owing to light scattering. In the intact
brain, fMRI is routinely applied to monitor changes in blood-ox-
ygen-level-dependent (BOLD) signals. BOLD signals can be
modulated by optogenetic stimulation of endogenous neurons
at the site of stimulation and in connected brain regions distant
from the stimulus (Lee et al., 2010). If applied to a stem cell graft,
optogenetic fMRI could reveal the functional impact of the graft
in the entire host nervous system.
In Vivo Imaging
Established techniques to monitor the functional consequences
of stem cell grafts mostly rely on PET imaging. For example,
various aspects of dopaminergic re-innervation have been
imaged in preclinical models (Grealish et al., 2014) and in PD pa-
tients with fetal grafts (Ma et al., 2010). Structurally, grafts can be
followed after labeling with superparamagnetic iron oxide nano-
particles (SPIONS) (Thu et al., 2012) or reporter genes (i.e., lucif-
erase, transferrin) that have been successfully used in clinical
studies. These in vivo imaging techniques designed to trace
stem cell grafts are the topic of a recent detailed review (Duffy
et al., 2014).
Transsynaptic Tracing
In addition to the tools that define functional connectivity, several
anterograde and retrograde transsynaptic tracers exist (Call-
away, 2008), which if successfully applied to a stem cell graft
could anatomically map the graft’s functional connections.
Wheat germ agglutinin (WGA) is transported anterogradely and
retrogradely and can be coupled to CRE recombinase to initiate
expression of a floxed marker protein in a transsynaptically con-
nected population (Gradinaru et al., 2010). Similarly, the non-
toxic fragment of tetanus toxin coupled to a fluorescent marker
(GFP-TTC) can be used to label retrograde connections (Maskos
et al., 2002). The only transsynaptic labeling strategy so far suc-
cessfully applied to a stem cell graft employed a pseudo-typed
rabies virus (Garcia et al., 2012). Retrograde transfer of an
EGFP tagged rabies virus labeled functionally connected up-
stream neurons efficiently in vitro and in vivo (Figure 3D).
Gene Editing
Another recent advance that will greatly facilitate mechanistic
studies in neural repair is the use of novel genome engineering
techniques such as CRISPR/Cas9 based gene editing (Hsu
et al., 2014), a technique already in routine use for hPSC studies
(Hou et al., 2013; Mali et al., 2013). Beyond the applications in
basic stem cell biology, these technologies should also be useful
in generating hPSC-derived donor cells deficient in one or
several candidate therapeutic factors analogous to classic
loss-of-function experiments in the mouse. Thereby, adequatecontrol populations could be generated for paradigms where
the therapeuticmechanism is likely to involve factors such as tro-
phic support, enzyme replacement, immunomodulation, or mye-
lination.
Conclusions
Over the last two decades the field of stem cell-based repair
has moved from basic science to promising preclinical results
and early stage clinical trials. The push toward translation will
only increase over the next few years driven in part by the suc-
cesses in generating disease-relevant human cell types at scale
and under cGMP conditions. There is also considerable pres-
sure from the patient community and the public at large as
well as the various funding agencies that have supported
stem cell research to make human stem cell-based therapies
a reality. The next few years will likely be an exciting period
with many potential cell sources, differentiation strategies,
and disease targets to be pursued. However, we argue that
for the long-term implementation of stem cell based therapies,
it will be essential to critically assess their mechanism of action.
Only then can we safely transplant cells into patients where
they will assume lifelong function—a setting nearly impossible
to mimic in preclinical models. The use of novel technologies
to interrogate graft function, such as optogenetics, transsynap-
tic tracers, or genetic gain or loss of function experiments,
should become routine in guiding therapeutic development
and in providing scientific rationale for cell choice or dose.
The time has come to translate basic findings toward the clinic.
In this process, mechanism-based approaches will allow the
field to progress effectively in order to move back and forth
from basic research to clinical application to generate a cell
product with optimal efficacy. Only if stem cell therapies
achieve disease-modifying activity or long-term functional im-
provements that are competitive or superior to existing thera-
pies will the field be able to progress beyond ‘‘first in human’’
studies toward meaningful therapies that may enter routine
medical practice over the next two decades to come.
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